Good morning, everyone, and how are you today? We would not be surprised to hear that many of you on this side of the pond may be a wee bit tired after tracking the extended drama over election results. After all, the right to vote is a good thing. And as our Bubbe taught us long ago, the only constant is change. So while you ponder what the future holds, please join us for a cup of stimulation and a quick look at the menu of tidbits we have provided. Hope your day goes well and, of course, do keep in touch. We enjoy the outreach …

After a pitched battle, former Celgene (CELG) chief executive Bob Hugin will not head to the U.S. Senate to represent New Jersey. The Democratic incumbent, Robert Menendez, prevailed in an especially nasty campaign in which Hugin was portrayed as a greedy pharma exec who repeatedly raised prices on a cancer drug and oversaw malfeasance because Celgene paid $280 million last year to settle a whistleblower lawsuit over allegedly illegal marketing tactics. For his part, Hugin ads reminded voters that Menendez was tried, unsuccessfully, for corruption. He also derided the “lies and mischaracterizations about the pharmaceutical industry. … We do such good things for all people around the world,” he told STAT.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy